{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:17:53Z","timestamp":1793305073724,"version":"4.5.0"},"publisher-location":"Cham","reference-count":145,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319596587","type":"print"},{"value":"9783319596594","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/164_2016_76","type":"book-chapter","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T02:54:05Z","timestamp":1478660045000},"page":"271-305","source":"Crossref","is-referenced-by-count":162,"title":["Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside"],"prefix":"10.1007","author":[{"given":"Peter","family":"Kolkhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Nowack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"76_CR1","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/eurheartj\/ehr170","volume":"32","author":"M Albaghdadi","year":"2011","unstructured":"Albaghdadi M, Gheorghiade M, Pitt B (2011) Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J 32:2626\u20132633","journal-title":"Eur Heart J"},{"key":"76_CR2","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR et al (2015) Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem 290:21876\u201321889","journal-title":"J Biol Chem"},{"key":"76_CR3","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1021\/jm1002827","volume":"53","author":"GB Arhancet","year":"2010","unstructured":"Arhancet GB, Woodard SS, Dietz JD, Garland DJ, Wagner GM, Iyanar K et al (2010a) Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem 53:4300\u20134304","journal-title":"J Med Chem"},{"key":"76_CR4","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","volume":"53","author":"GB Arhancet","year":"2010","unstructured":"Arhancet GB, Woodard SS, Iyanar K, Case BL, Woerndle R, Dietz JD et al (2010b) Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. J Med Chem 53:5970\u20135978","journal-title":"J Med Chem"},{"key":"76_CR5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268\u2013275","journal-title":"Science"},{"key":"76_CR6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. Mineralocorticoid Receptor Antagonist Tolerability Study\u2013Diabetic Nephropathy (ARTS-DN) Study Group. JAMA 314:884\u2013894","journal-title":"JAMA"},{"key":"76_CR7","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-P\u00e9rez S, Heckroth H et al (2012) Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7:1385\u20131403","journal-title":"ChemMedChem"},{"key":"76_CR8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1681\/ASN.2014121216","volume":"27","author":"J Barrera-Chimal","year":"2016","unstructured":"Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, Jaisser F (2016) Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. J Am Soc Nephrol 27:398\u2013404","journal-title":"J Am Soc Nephrol"},{"key":"76_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R (2015) Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 65:257\u2013263","journal-title":"Hypertension"},{"key":"76_CR10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","volume":"79","author":"JP Bertocchio","year":"2011","unstructured":"Bertocchio JP, Warnock DG, Jaisser F (2011) Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 79:1051\u20131060","journal-title":"Kidney Int"},{"key":"76_CR11","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/en.2011-2098","volume":"153","author":"LA Bienvenu","year":"2012","unstructured":"Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK et al (2012) Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 153:3416\u20133425","journal-title":"Endocrinology"},{"key":"76_CR12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/HYPERTENSIONAHA.115.05981","volume":"66","author":"LA Bienvenu","year":"2015","unstructured":"Bienvenu LA, Reichelt ME, Morgan J, Fletcher EK, Bell JR, Rickard AJ et al (2015) Cardiomyocyte mineralocorticoid receptor activation impairs acute cardiac functional recovery after ischemic insult. Hypertension 66:970\u2013977","journal-title":"Hypertension"},{"key":"76_CR13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355\u20131364","journal-title":"Circ Res"},{"key":"76_CR14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/HYPERTENSIONAHA.114.03936","volume":"65","author":"A Buglioni","year":"2015","unstructured":"Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG et al (2015) Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension 65:45\u201353","journal-title":"Hypertension"},{"key":"76_CR15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/00005344-200105000-00006","volume":"37","author":"G Cargnelli","year":"2001","unstructured":"Cargnelli G, Trevisi L, Debetto P, Luciani S, Bova S (2001) Effects of canrenone on aorta and right ventricle of the rat. J Cardiovasc Pharmacol 37:540\u2013547","journal-title":"J Cardiovasc Pharmacol"},{"key":"76_CR16","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.amjcard.2005.07.061","volume":"96","author":"AA Carr","year":"2005","unstructured":"Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahl\u00f6f B, Ibsen H et al (2005) Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 96:1530\u20131536","journal-title":"Am J Cardiol"},{"key":"76_CR17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jps.2600650919","volume":"65","author":"YW Chien","year":"1976","unstructured":"Chien YW, Hofmann LM, Lambert HJ, Tao LC (1976) Binding of spirolactones to human plasma proteins. J Pharm Sci 65:1337\u20131340","journal-title":"J Pharm Sci"},{"key":"76_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2005.03.016","volume":"239","author":"TY Chun","year":"2005","unstructured":"Chun TY, Pratt JH (2005) Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Mol Cell Endocrinol 239:55\u201361","journal-title":"Mol Cell Endocrinol"},{"key":"76_CR19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","volume":"89","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P et al (2002) Relation of aldosterone \u201cescape\u201d despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in CHF secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 89:403\u2013407","journal-title":"Am J Cardiol"},{"key":"76_CR20","doi-asserted-by":"crossref","unstructured":"Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology (2003) The EuroHeart Failure survey programme \u2013 a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 24:442\u2013463","DOI":"10.1016\/S0195-668X(02)00823-0"},{"key":"76_CR21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/13543776.2014.854772","volume":"24","author":"M Collin","year":"2014","unstructured":"Collin M, Jaisser F (2014) Mineralocorticoid receptor modulators: a patent review (2007\u20132012). Expert Opin Ther Pat 24:177\u2013183","journal-title":"Expert Opin Ther Pat"},{"key":"76_CR22","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","volume":"31","author":"CS Cook","year":"2003","unstructured":"Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW (2003) Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 31:1448\u20131455","journal-title":"Drug Metab Dispos"},{"key":"76_CR23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1172\/JCI101338","volume":"21","author":"DC Darrow","year":"1942","unstructured":"Darrow DC, Miller HC (1942) Production of cardiac lesions by repeated injections of desoxycorticosterone acetate. J Clin Invest 21:601\u2013611","journal-title":"J Clin Invest"},{"key":"76_CR24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","volume":"240","author":"M Gasparo de","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjou\u00e9 HP, Whitebread SE, Haenni H, Schenkel L et al (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650\u2013656","journal-title":"J Pharmacol Exp Ther"},{"key":"76_CR25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd2398","volume":"6","author":"AR Lera de","year":"2007","unstructured":"de Lera AR, Bourguet W, Altucci L, Gronemeyer H (2007) Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 6:811\u2013820","journal-title":"Nat Rev Drug Discov"},{"key":"76_CR26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D Zeeuw de","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921\u2013927","journal-title":"Circulation"},{"key":"76_CR27","doi-asserted-by":"crossref","unstructured":"Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R et al (2011) Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162:966.e10\u2013972.e10","DOI":"10.1016\/j.ahj.2011.09.007"},{"key":"76_CR28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","volume":"51","author":"JD Dietz","year":"2008","unstructured":"Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR et al (2008) A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51:742\u2013748","journal-title":"Hypertension"},{"key":"76_CR29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ageing\/afi104","volume":"34","author":"C Dinsdale","year":"2005","unstructured":"Dinsdale C, Wani M, Steward J, O\u2019Mahony MS (2005) Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing 34:395\u2013398","journal-title":"Age Ageing"},{"key":"76_CR30","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(88)90742-8","volume":"2","author":"CR Edwards","year":"1988","unstructured":"Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS et al (1988) Localisation of 11 beta-hydroxysteroid dehydrogenase \u2013 tissue specific protector of the mineralocorticoid receptor. Lancet 2:986\u2013989","journal-title":"Lancet"},{"key":"76_CR31","volume-title":"Fluorenone 1, 4,-dihydropyridin derivatives, WO\/2005\/087740","author":"JK Ergueden","year":"2005","unstructured":"Ergueden JK, Kolkhof P, Sandner P, Kuhl A, Stasch JP, Pook E, Schlemmer KH (2005) Fluorenone 1, 4,-dihydropyridin derivatives, WO\/2005\/087740. Bayer Healthcare AG, Wuppertal"},{"key":"76_CR32","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","volume":"285","author":"J Fagart","year":"2010","unstructured":"Fagart J, Hillisch A, Huyet J, B\u00e4rfacker L, Fay M, Pleiss U et al (2010) A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 285:29932\u201329940","journal-title":"J Biol Chem"},{"key":"76_CR33","doi-asserted-by":"crossref","first-page":"H2035","DOI":"10.1152\/ajpheart.00552.2010","volume":"300","author":"J Favre","year":"2011","unstructured":"Favre J, Gao J, Zhang AD, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B et al (2011) Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 300:H2035\u2013H2043","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"76_CR34","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 37:2105\u20132114, PMID: 27130705","journal-title":"Eur Heart J"},{"key":"76_CR35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","volume":"123","author":"D Fraccarollo","year":"2011","unstructured":"Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Sch\u00fctz G et al (2011) Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123:400\u2013408","journal-title":"Circulation"},{"key":"76_CR36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11906-003-0012-2","volume":"5","author":"M Fritsch Neves","year":"2003","unstructured":"Fritsch Neves M, Schiffrin EL (2003) Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 5:59\u201365","journal-title":"Curr Hypertens Rep"},{"key":"76_CR37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","volume":"46","author":"PJ Fuller","year":"2005","unstructured":"Fuller PJ, Young MJ (2005) Mechanisms of mineralocorticoid action. Hypertension 46:1227\u20131235","journal-title":"Hypertension"},{"key":"76_CR38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0039-128X(94)90096-5","volume":"59","author":"JW Funder","year":"1994","unstructured":"Funder JW (1994) Enzymes and receptors: challenges and future directions. Steroids 59:164\u2013169","journal-title":"Steroids"},{"key":"76_CR39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00041552-200103000-00011","volume":"10","author":"JW Funder","year":"2001","unstructured":"Funder JW (2001) Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens 10:227\u2013230","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"76_CR40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tem.2004.03.006","volume":"15","author":"JW Funder","year":"2004","unstructured":"Funder JW (2004) Is aldosterone bad for the heart? Trends Endocrinol Metab 15:139\u2013142","journal-title":"Trends Endocrinol Metab"},{"key":"76_CR41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jsbmb.2004.12.010","volume":"93","author":"JW Funder","year":"2005","unstructured":"Funder JW (2005a) RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93:121\u2013125","journal-title":"J Steroid Biochem Mol Biol"},{"key":"76_CR42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ncpendmet0016","volume":"1","author":"JW Funder","year":"2005","unstructured":"Funder JW (2005b) Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab 1:4\u20135","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"76_CR43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","volume":"53","author":"JW Funder","year":"2009","unstructured":"Funder JW (2009) Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53:286\u2013290","journal-title":"Hypertension"},{"key":"76_CR44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","volume":"242","author":"JW Funder","year":"1988","unstructured":"Funder JW, Pearce PT, Smith R, Smith AI (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583\u2013585","journal-title":"Science"},{"key":"76_CR45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27\u201331","journal-title":"Mol Cell Endocrinol"},{"key":"76_CR46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","volume":"289","author":"DS Geller","year":"2000","unstructured":"Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A et al (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119\u2013123","journal-title":"Science"},{"issue":"1","key":"76_CR47","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","volume":"127","author":"AS Go","year":"2013","unstructured":"Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB et al (2013) Heart disease and stroke statistics \u2013 2013 update: a report from the American Heart Association. Circulation 127(1):e6\u2013e245","journal-title":"Circulation"},{"key":"76_CR48","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.108.805804","volume":"119","author":"AM G\u00f3mez","year":"2009","unstructured":"G\u00f3mez AM, Rueda A, Sainte-Marie Y, Pereira L, Zissimopoulos S, Zhu X et al (2009) Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 119:2179\u20132187","journal-title":"Circulation"},{"key":"76_CR49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","volume":"67","author":"J Grune","year":"2016","unstructured":"Grune J, Benz V, Brix S, Salatzki J, Blumrich A, H\u00f6ft B et al (2016) Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol 67:402\u2013411","journal-title":"J Cardiovasc Pharmacol"},{"key":"76_CR50","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G G\u00fcder","year":"2007","unstructured":"G\u00fcder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G et al (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115:1754\u20131761","journal-title":"Circulation"},{"key":"76_CR51","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","volume":"67","author":"A Gueret","year":"2016","unstructured":"Gueret A, Harouki N, Favre J, Galmiche G, Nicol L, Henry JP et al (2016) Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension 67:717\u2013723","journal-title":"Hypertension"},{"key":"76_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.263","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S (2016) Pharmacokinetics of the novel Non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment. Clin Pharmacol Drug Dev. doi: 10.1002\/cpdd.263","journal-title":"Clin Pharmacol Drug Dev"},{"key":"76_CR53","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1681\/ASN.2012111094","volume":"25","author":"LL Huang","year":"2014","unstructured":"Huang LL, Nikolic-Paterson DJ, Han Y, Ozols E, Ma FY, Young MJ, Tesch GH (2014) Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol 25:2231\u20132240","journal-title":"J Am Soc Nephrol"},{"key":"76_CR54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1152\/physrev.00008.2012","volume":"93","author":"Y Imai","year":"2013","unstructured":"Imai Y, Youn MY, Inoue K, Takada I, Kouzmenko A, Kato S (2013) Nuclear receptors in bone physiology and diseases. Physiol Rev 93:481\u2013523","journal-title":"Physiol Rev"},{"key":"76_CR55","unstructured":"Inspra Drug Approval Package (2003) Pharmacological Review Inspra Drug Approval Package 21-437\/S-002, FDA US Food and Drug Administration. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-437S002_Inspra_Pharmr.pdf"},{"key":"76_CR56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","volume":"68","author":"F Jaisser","year":"2016","unstructured":"Jaisser F, Farman N (2016) Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev 68:49\u201375","journal-title":"Pharmacol Rev"},{"key":"76_CR57","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/HYPERTENSIONAHA.115.06015","volume":"66","author":"G Jia","year":"2015","unstructured":"Jia G, Habibi J, DeMarco VG, Martinez-Lemus LA, Ma L, Whaley-Connell AT et al (2015) Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension 66:1159\u20131167","journal-title":"Hypertension"},{"key":"76_CR58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pds.1923","volume":"19","author":"ES Johnson","year":"2010","unstructured":"Johnson ES, Weinstein JR, Thorp ML, Platt RW, Petrik AF, Yang X et al (2010) Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf 19:266\u2013272","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"76_CR59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543\u2013551","journal-title":"N Engl J Med"},{"key":"76_CR60","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","volume":"126","author":"CM Kagawa","year":"1957","unstructured":"Kagawa CM, Cella JA, Van Arman CG (1957) Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126:1015\u20131016","journal-title":"Science"},{"key":"76_CR61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/03602537808993782","volume":"8","author":"A Karim","year":"1978","unstructured":"Karim A (1978) Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev 8:151\u2013188","journal-title":"Drug Metab Rev"},{"key":"76_CR62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1159\/000368470","volume":"39","author":"HY Kim","year":"2014","unstructured":"Kim HY, Bae EH, Ma SK, Kim SW (2014) Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with proteinuria. Kidney Blood Press Res 39:573\u2013580","journal-title":"Kidney Blood Press Res"},{"key":"76_CR63","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","volume":"350","author":"P Kolkhof","year":"2012","unstructured":"Kolkhof P, Borden SA (2012) Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 350:310\u2013317","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl 1","key":"76_CR64","first-page":"110","volume":"27","author":"P Kolkhof","year":"2006","unstructured":"Kolkhof P, Flamme I, Figueroa-P\u00e9rez S, Baerfacker L, Hartmann E, Rinke M, Sch\u00e4fer S (2006) Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive hypertension [abstract P754]. Eur Heart J 27(Suppl 1):110","journal-title":"Eur Heart J"},{"key":"76_CR65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L et al (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64:69\u201378","journal-title":"J Cardiovasc Pharmacol"},{"key":"76_CR66","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","volume":"24","author":"P Kolkhof","year":"2015","unstructured":"Kolkhof P, Nowack C, Eitner F (2015) Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 24:417\u2013424","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"76_CR67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2010.03.018","volume":"635","author":"H Kosaka","year":"2010","unstructured":"Kosaka H, Hirayama K, Yoda N, Sasaki K, Kitayama T, Kusaka H, Matsubara M (2010) The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 635:49\u201355","journal-title":"Eur J Pharmacol"},{"key":"76_CR68","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1210\/jcem-18-11-1237","volume":"18","author":"RL Landau","year":"1958","unstructured":"Landau RL, Lugibihl K (1958) Inhibition of the sodium-retaining influence of aldosterone by progesterone. J Clin Endocrinol Metab 18:1237\u20131245","journal-title":"J Clin Endocrinol Metab"},{"key":"76_CR69","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1210\/jcem-15-10-1194","volume":"15","author":"RL Landau","year":"1955","unstructured":"Landau RL, Bergenstal DM, Lugibihl K, Kascht ME (1955) The metabolic effects of progesterone in man. J Clin Endocrinol Metab 15:1194\u20131215","journal-title":"J Clin Endocrinol Metab"},{"key":"76_CR70","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","volume":"289","author":"D Lavall","year":"2014","unstructured":"Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Sch\u00e4fers HJ et al (2014) The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289:6656\u20136668","journal-title":"J Biol Chem"},{"key":"76_CR71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G (2016) Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone \u2013 results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol 30:172\u2013184","journal-title":"Fundam Clin Pharmacol"},{"issue":"10","key":"76_CR72","volume":"9","author":"C Li","year":"2014","unstructured":"Li C, Zhang YY, Frieler RA, Zheng XJ, Zhang WC, Sun XN et al (2014) Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One 9(10), e110950","journal-title":"PLoS One"},{"key":"76_CR73","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","volume":"24","author":"LC Liu","year":"2015","unstructured":"Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA (2015) Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs 24:1123\u20131135","journal-title":"Expert Opin Investig Drugs"},{"key":"76_CR74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","volume":"71","author":"M Lombes","year":"1992","unstructured":"Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP (1992) Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71:503\u2013510","journal-title":"Circ Res"},{"key":"76_CR75","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","volume":"57","author":"A Lother","year":"2011","unstructured":"Lother A, Berger S, Gilsbach R, R\u00f6sner S, Ecke A, Barreto F et al (2011) Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57:746\u2013754","journal-title":"Hypertension"},{"key":"76_CR76","doi-asserted-by":"crossref","first-page":"8.1","DOI":"10.1146\/annurev-pharmtox-010814-124302","volume":"55","author":"A Lother","year":"2015","unstructured":"Lother A, Moser M, Bode C, Feldman RD, Hein L (2015) Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol 55:8.1\u20138.24","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"76_CR77","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.115.06530","volume":"67","author":"A Lother","year":"2016","unstructured":"Lother A, Furst D, Bergemann S, Gilsbach R, Grahammer F, Huber TB et al (2016) Deoxycorticosterone acetate\/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension 67:130\u2013138","journal-title":"Hypertension"},{"key":"76_CR78","volume":"10","author":"FY Ma","year":"2015","unstructured":"Ma FY, Han Y, Nikolic-Paterson DJ, Kolkhof P, Tesch GH (2015) Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628. PLoS One 10, e0145666","journal-title":"PLoS One"},{"key":"76_CR79","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Dahlstr\u00f6m U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al (2013) EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 15:808\u2013817","journal-title":"Eur J Heart Fail"},{"key":"76_CR80","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.1963.73700230005018","volume":"184","author":"N Mann","year":"1963","unstructured":"Mann N (1963) Gynecomastia during therapy with spironolactone. JAMA 184:778\u2013780","journal-title":"JAMA"},{"key":"76_CR81","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.mce.2011.09.011","volume":"350","author":"V Marzolla","year":"2012","unstructured":"Marzolla V, Armani A, Zennaro MC, Cinti F, Mammi C, Fabbri A et al (2012) The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol 350:281\u2013288","journal-title":"Mol Cell Endocrinol"},{"key":"76_CR82","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2010.04.149","volume":"396","author":"T Matsui","year":"2010","unstructured":"Matsui T, Takeuchi M, Yamagishi S (2010) Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun 396:566\u2013570","journal-title":"Biochem Biophys Res Commun"},{"key":"76_CR83","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","volume":"25","author":"TA Mavrakanas","year":"2014","unstructured":"Mavrakanas TA, Gariani K, Martin PY (2014) Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy. Eur J Intern Med 25:173\u2013176","journal-title":"Eur J Intern Med"},{"key":"76_CR84","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0735-1097(01)01700-4","volume":"39","author":"PA McCullough","year":"2002","unstructured":"McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD (2002) Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39:60\u201369","journal-title":"J Am Coll Cardiol"},{"key":"76_CR85","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0022-4731(81)90046-7","volume":"14","author":"WJ Meyer","year":"1981","unstructured":"Meyer WJ, Nichols NR (1981) Mineralocorticoid binding in cultured smooth muscle cells and fibroblasts from rat aorta. J Steroid Biochem 14:1157\u20131168","journal-title":"J Steroid Biochem"},{"key":"76_CR86","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm100505n","volume":"53","author":"MJ Meyers","year":"2010","unstructured":"Meyers MJ, Arhancet GB, Hockerman SL, Chen X, Long SA, Mahoney MW et al (2010) Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 53:5979\u20136002","journal-title":"J Med Chem"},{"key":"76_CR87","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","volume":"93","author":"A Mosterd","year":"2007","unstructured":"Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137\u20131146","journal-title":"Heart"},{"issue":"Abstract Supple","key":"76_CR145","first-page":"829","volume":"37","author":"P Mulder","year":"2016","unstructured":"Mulder P, BarreraChimal J, El Moghrabi S, Kolkhof P, Ouvrard-Pascaud A, Jaisser F (2016) Finerenone improves diastolic function in a preclinical model of type2 diabetes mellitus. Eur Heart J 37(Abstract Supplement):829","journal-title":"Eur Heart J"},{"key":"76_CR88","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","volume":"47","author":"K Nagata","year":"2006","unstructured":"Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H et al (2006) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47:656\u2013664","journal-title":"Hypertension"},{"key":"76_CR89","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1096\/fj.09-147926","volume":"24","author":"A Nguyen Dinh Cat","year":"2010","unstructured":"Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N et al (2010) The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 24:2454\u20132463","journal-title":"FASEB J"},{"key":"76_CR90","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ahj.2008.04.030","volume":"156","author":"CM O\u2019Connor","year":"2008","unstructured":"O\u2019Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M et al (2008) Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 156:662\u2013673","journal-title":"Am Heart J"},{"key":"76_CR91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","volume":"4","author":"S Orena","year":"2013","unstructured":"Orena S, Maurer TS, She L, Eudy R, Bernardo V, Dash D et al (2013) PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol 4:115","journal-title":"Front Pharmacol"},{"key":"76_CR92","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","volume":"111","author":"A Ouvrard-Pascaud","year":"2005","unstructured":"Ouvrard-Pascaud A, Sainte-Marie Y, B\u00e9nitah JP, Perrier R, Soukaseum C, Nguyen Dinh Cat A et al (2005) Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111:3025\u20133033","journal-title":"Circulation"},{"issue":"3","key":"76_CR93","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251\u2013259","journal-title":"N Engl J Med"},{"key":"76_CR94","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"Parthasarathy HK, M\u00e9nard J, White WB, Young WF Jr, Williams GH, Williams B et al (2011) A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 29:980\u2013990","journal-title":"J Hypertens"},{"key":"76_CR95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N et al (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:34\u201342","journal-title":"Circulation"},{"key":"76_CR96","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1021\/jm300806c","volume":"55","author":"DW Piotrowski","year":"2012","unstructured":"Piotrowski DW (2012) Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J Med Chem 55:7957\u20137966","journal-title":"J Med Chem"},{"key":"76_CR97","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"key":"76_CR98","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"76_CR99","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","volume":"14","author":"B Pitt","year":"2012","unstructured":"Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P et al (2012) Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 14:668\u20136675","journal-title":"Eur J Heart Fail"},{"key":"76_CR100","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34:2453\u20132463","journal-title":"Eur Heart J"},{"key":"76_CR101","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"76_CR102","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H et al (2015) Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone versus eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease. Eur J Heart Fail 17:224\u2013232","journal-title":"Eur J Heart Fail"},{"key":"76_CR103","first-page":"1801","volume":"22","author":"D Platt","year":"1972","unstructured":"Platt D, Pauli H (1972) Studies on organ- and subcellular distribution of [3H]spironolactone in animals [in German]. Arzneimittelforschung 22:1801\u20131802","journal-title":"Arzneimittelforschung"},{"key":"76_CR104","doi-asserted-by":"publisher","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al; Authors\/Task Force Members; Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. doi: 10.1002\/ejhf.592","DOI":"10.1002\/ejhf.592"},{"key":"76_CR105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/hlca.193802101149","volume":"21","author":"T Reichstein","year":"1938","unstructured":"Reichstein T, von Euw J (1938) \u00dcber Bestandteile der Nebennierenrinde. Isolierung der Substanzen Q (Desoxy-Corticosteron) und R sowie weiterer Stoffe. Helvet Chim Acta 21:1197\u20131210","journal-title":"Helvet Chim Acta"},{"key":"76_CR106","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","volume":"54","author":"AJ Rickard","year":"2009","unstructured":"Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54:537\u2013543","journal-title":"Hypertension"},{"key":"76_CR107","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","volume":"60","author":"AJ Rickard","year":"2012","unstructured":"Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ et al (2012) Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis. Hypertension 60:1443\u20131450","journal-title":"Hypertension"},{"key":"76_CR108","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.113.01803","volume":"63","author":"AJ Rickard","year":"2014","unstructured":"Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ (2014) Endothelial cell mineralocorticoid receptors regulate DOC\/salt-mediated cardiac remodeling and vascular reactivity, but not blood pressure. Hypertension 63:1033\u20131040","journal-title":"Hypertension"},{"key":"76_CR109","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA et al (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H1802\u2013H1810","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"76_CR110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0039-128X(99)00087-2","volume":"65","author":"FM Rogerson","year":"2000","unstructured":"Rogerson FM, Fuller PJ (2000) Mineralocorticoid action. Steroids 65:61\u201373","journal-title":"Steroids"},{"key":"76_CR111","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0735-1097(94)90001-9","volume":"24","author":"JL Rouleau","year":"1994","unstructured":"Rouleau JL, Packer M, Moy\u00e9 L, de Champlain J, Bichet D, Klein M et al (1994) Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 24:583\u2013591","journal-title":"J Am Coll Cardiol"},{"key":"76_CR112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","volume":"34","author":"GC Roush","year":"2016","unstructured":"Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA (2016) Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens 34:11\u201319","journal-title":"J Hypertens"},{"key":"76_CR113","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000371497","volume":"40","author":"LM Ruilope","year":"2014","unstructured":"Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H et al (2014) Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol 40:572\u2013581","journal-title":"Am J Nephrol"},{"key":"76_CR114","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","volume":"80","author":"N Sato","year":"2016","unstructured":"Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T et al (2016) ARTS-HF Japan Study Group. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease. Circ J 80:1113\u20131122","journal-title":"Circ J"},{"key":"76_CR115","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1096\/fj.10-173286","volume":"25","author":"N Schupp","year":"2011","unstructured":"Schupp N, Kolkhof P, Queisser N, G\u00e4rtner S, Schmid U, Kretschmer A et al (2011) Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 25:968\u2013978","journal-title":"FASEB J"},{"key":"76_CR116","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","volume":"22","author":"MH Schwenk","year":"2015","unstructured":"Schwenk MH, Hirsch JS, Bomback AS (2015) Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis 22:123\u2013132","journal-title":"Adv Chronic Kidney Dis"},{"key":"76_CR117","first-page":"515","volume":"47","author":"H Selye","year":"1942","unstructured":"Selye H (1942) Production of nephrosclerosis by overdosage with desoxycorticosterone acetate. Can Med Assoc J 47:515\u2013519","journal-title":"Can Med Assoc J"},{"key":"76_CR118","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/jcem-6-2-117","volume":"6","author":"H Selye","year":"1946","unstructured":"Selye H (1946) The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab 6:117\u2013230","journal-title":"J Clin Endocrinol Metab"},{"key":"76_CR119","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1126\/science.121.3141.368","volume":"121","author":"H Selye","year":"1955","unstructured":"Selye H (1955) Anticortisol action of aldosterone. Science 121:368\u2013369","journal-title":"Science"},{"key":"76_CR120","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","volume":"295","author":"Y Shang","year":"2002","unstructured":"Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295:2465\u20132468","journal-title":"Science"},{"key":"76_CR121","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","volume":"10","author":"DA Sica","year":"2005","unstructured":"Sica DA (2005) Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10:23\u201329","journal-title":"Heart Fail Rev"},{"key":"76_CR122","first-page":"9","volume-title":"Memoirs of the Society for Endocrinology, No. 2. The determination of adrenal cortical steroids and their metabolites","author":"SA Simpson","year":"1953","unstructured":"Simpson SA, Tait JF (1953) Memoirs of the Society for Endocrinology, No. 2. The determination of adrenal cortical steroids and their metabolites. Dennis Dobson, Ltd., London, p 9"},{"key":"76_CR123","doi-asserted-by":"crossref","unstructured":"Simpson SA, Tait JF, Wettstein A, Neher R, v. Euw J, Schindler O, Reichstein T (1954) Constitution of aldosterone, a new mineralocorticoid. Experientia 10:132\u2013133","DOI":"10.1007\/BF02158515"},{"key":"76_CR124","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"J Staessen","year":"1981","unstructured":"Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91:457\u2013465","journal-title":"J Endocrinol"},{"key":"76_CR125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbrc.2005.08.056","volume":"336","author":"T Sugiyama","year":"2005","unstructured":"Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K et al (2005) Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 336:163\u2013167","journal-title":"Biochem Biophys Res Commun"},{"key":"76_CR126","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","volume":"102","author":"I Sungaila","year":"1992","unstructured":"Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E (1992) Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 102:1680\u20131685","journal-title":"Gastroenterology"},{"key":"76_CR127","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","volume":"10","author":"M Svensson","year":"2004","unstructured":"Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D (2004) How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 10:297\u2013303","journal-title":"J Card Fail"},{"key":"76_CR128","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82:1730\u20131736","journal-title":"Circulation"},{"key":"76_CR129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.semnephrol.2014.04.005","volume":"34","author":"J Tamargo","year":"2014","unstructured":"Tamargo J, Solini A, Ruilope LM (2014) Comparison of agents that affect aldosterone action. Semin Nephrol 34:285\u2013306","journal-title":"Semin Nephrol"},{"key":"76_CR130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/HYPERTENSIONAHA.115.05431","volume":"66","author":"A Tarjus","year":"2015","unstructured":"Tarjus A, Mart\u00ednez-Mart\u00ednez E, Amador C, Latouche C, El Moghrabi S, Berger T et al (2015) Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension 66:158\u2013166","journal-title":"Hypertension"},{"key":"76_CR131","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.68.3.299","volume":"68","author":"GW Thorn","year":"1938","unstructured":"Thorn GW, Engel LL (1938) The effect of sex hormones on the renal excretion of electrolytes. J Exp Med 68:299\u2013312","journal-title":"J Exp Med"},{"key":"76_CR132","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1172\/JCI101060","volume":"18","author":"GW Thorn","year":"1939","unstructured":"Thorn GW, Howard RP, Emerson K (1939) Treatment of Addison\u2019s disease with desoxy-corticosterone acetate, a synthetic adrenal cortical hormone (preliminary report). J Clin Invest 18:449\u2013467","journal-title":"J Clin Invest"},{"key":"76_CR133","unstructured":"Thosar SS, Gokhale RD, Tolbert DS (2003) Immediate Release Eplerenone Compositions, US 6, 558, 707(B1). G.D. Searle & Co., US"},{"issue":"3","key":"76_CR134","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/eurheartj\/ehm554","volume":"29","author":"C Tribouilloy","year":"2008","unstructured":"Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M et al (2008) Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 29(3):339\u2013347","journal-title":"Eur Heart J"},{"key":"76_CR135","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","volume":"120","author":"MG Usher","year":"2010","unstructured":"Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G et al (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120:3350\u20133364","journal-title":"J Clin Invest"},{"key":"76_CR136","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15:709\u2013716","journal-title":"Am J Hypertens"},{"key":"76_CR137","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/eurjhf\/hfr129","volume":"13","author":"RA Weir","year":"2011","unstructured":"Weir RA, Tsorlalis IK, Steedman T, Dargie HJ, Fraser R, McMurray JJ, Connell JM (2011) Aldosterone and cortisol predict medium-term left ventricular remodeling following myocardial infarction. Eur J Heart Fail 13:1305\u20131313","journal-title":"Eur J Heart Fail"},{"key":"76_CR138","doi-asserted-by":"crossref","unstructured":"Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, Adhere Scientific Advisory Committee and Investigators (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47:76\u201384","DOI":"10.1016\/j.jacc.2005.09.022"},{"key":"76_CR139","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 128:e240\u2013e327","journal-title":"Circulation"},{"key":"76_CR140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","volume":"27","author":"J Yang","year":"2016","unstructured":"Yang J, Young MJ (2016) Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol 27:78\u201385","journal-title":"Curr Opin Pharmacol"},{"key":"76_CR141","doi-asserted-by":"crossref","first-page":"F1519","DOI":"10.1152\/ajprenal.00605.2007","volume":"295","author":"L Yu","year":"2008","unstructured":"Yu L, Helms MN, Yue Q, Eaton DC (2008) Single-channel analysis of functional epithelial sodium channel (ENaC) stability at the apical membrane of A6 distal kidney cells. Am J Physiol Renal Physiol 295:F1519\u2013F1527","journal-title":"Am J Physiol Renal Physiol"},{"key":"76_CR142","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102:2700\u20132706","journal-title":"Circulation"},{"key":"76_CR143","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321","journal-title":"N Engl J Med"},{"key":"76_CR144","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","volume":"33","author":"F Zannad","year":"2012","unstructured":"Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K et al (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 33:2782\u20132795","journal-title":"Eur Heart J"}],"container-title":["Handbook of Experimental Pharmacology","Heart Failure"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2016_76","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T01:40:04Z","timestamp":1749692404000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2016_76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319596587","9783319596594"],"references-count":145,"URL":"https:\/\/doi.org\/10.1007\/164_2016_76","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}